Bioventus (BVS) Accumulated Expenses (2020 - 2026)

Bioventus' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $101.1 million for Q1 2026.

• Quarterly Accumulated Expenses fell 2.08% year-over-year to $101.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $101.1 million (down 2.08% YoY) and the FY2025 annual result came in at $130.2 million, down 4.15% from the prior year.
• Accumulated Expenses was $101.1 million for Q1 2026 at Bioventus, down from $130.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $146.8 million in Q3 2022 and bottomed at $101.1 million in Q1 2026.
• A 5-year average of $121.3 million and a median of $119.4 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 39.44% — and 2025, when it dropped 18.8%.
• Bioventus' Accumulated Expenses stood at $111.6 million in 2022, then grew by 7.37% to $119.8 million in 2023, then climbed by 13.43% to $135.9 million in 2024, then retreated by 4.15% to $130.2 million in 2025, then declined by 22.35% to $101.1 million in 2026.
• Business Quant data shows BVS's Accumulated Expenses at $101.1 million in Q1 2026, $130.2 million in Q4 2025, and $119.4 million in Q3 2025.